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BSTRACT
 
Background
 
Diabetic nephropathy is the leading
cause of end-stage renal disease. Interruption of the
renin–angiotensin system slows the progression of
renal disease in patients with type 1 diabetes, but sim-
ilar data are not available for patients with type 2, the
most common form of diabetes. We assessed the role
of the angiotensin-II–receptor antagonist losartan in
patients with type 2 diabetes and nephropathy.
 
Methods
 
A total of 1513 patients were enrolled in
this randomized, double-blind study comparing losar-
tan (50 to 100 mg once daily) with placebo, both taken
in addition to conventional antihypertensive treatment
(calcium-channel antagonists, diuretics, alpha-block-
ers, beta-blockers, and centrally acting agents), for a
mean of 3.4 years. The primary outcome was the com-
posite of a doubling of the base-line serum creatinine
concentration, end-stage renal disease, or death. Sec-
ondary end points included a composite of morbidi-
ty and mortality from cardiovascular causes, protein-
uria, and the rate of progression of renal disease.
 
Results
 
A total of 327 patients in the losartan
group reached the primary end point, as compared
with 359 in the placebo group (risk reduction, 16 per-
cent; P=0.02). Losartan reduced the incidence of a
doubling of the serum creatinine concentration (risk
reduction, 25 percent; P=0.006) and end-stage renal
disease (risk reduction, 28 percent; P=0.002) but had
no effect on the rate of death. The benefit exceeded
that attributable to changes in blood pressure. The
composite of morbidity and mortality from cardiovas-
cular causes was similar in the two groups, although
the rate of first hospitalization for heart failure was
significantly lower with losartan (risk reduction, 32
percent; P=0.005). The level of proteinuria declined
by 35 percent with losartan (P<0.001 for the compar-
ison with placebo).
 
Conclusions 
 
Losartan conferred significant renal
benefits in patients with type 2 diabetes and nephrop-
athy, and it was generally well tolerated. (N Engl J
Med 2001;345:861-9.)
 
Copyright © 2001 Massachusetts Medical Society.
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NTERRUPTION of the renin–angiotensin sys-
tem with angiotensin-I–converting enzyme in-
hibitors slows the progression of renal disease
both in patients with type 1 diabetes and in non-
diabetic patients who have overt nephropathy.
 
1-3
 
 How-
ever, postponing end-stage renal disease in patients
with type 2 diabetes, the leading cause of chronic renal
failure in many countries, remains an elusive goal. We
I
 
undertook a study in patients with type 2 diabetes
and nephropathy in order to determine whether the
angiotensin-II–receptor antagonist losartan, alone or
in combination with conventional antihypertensive
therapy, would increase the time to a doubling of the
serum creatinine concentration, the onset of end-
stage renal disease, or death. In addition, we assessed
the effects of losartan and placebo on the following
secondary end points: a composite of morbidity and
mortality from cardiovascular causes, proteinuria, and
the rate of progression of renal disease.
 
METHODS
 
Study Design
 
The Reduction of Endpoints in NIDDM with the Angiotensin II
Antagonist Losartan Study was an investigator-initiated, multina-
tional, double-blind, randomized, placebo-controlled study de-
signed to evaluate the renoprotective effects of losartan in 1513
patients with type 2 diabetes and nephropathy. The study design
has been described previously.
 
4
 
 In brief, 250 centers in 28 countries
in Asia, Europe, Central America, South America, and North Amer-
ica participated. The study protocol was approved by the institu-
tional review board of each center, and all patients gave written
informed consent. The study was overseen by steering and safety
committees, each of which contained one nonvoting member who
was an employee of the sponsoring pharmaceutical company. The
steering committee oversaw the study design, the conduct of the
trial, and the management and analysis of the data. A writing sub-
committee of the steering committee prepared this report. An in-
dependent end-points committee whose members were unaware of
the patients’ treatment assignments reviewed the data to determine
which patients had reached the end points.
We planned to complete the study 3.5 years after the last patient
underwent randomization, which would have resulted in a mean
follow-up time of 4.5 years. However, the study was discontinued
early (February 10, 2001) by a unanimous vote of the steering com-
mittee, whose members were unaware of the treatment assign-
ments. Their decision was based on new evidence suggesting that
angiotensin-I–converting enzyme inhibitors, which were excluded
by design from the study, may be effective in reducing the incidence
of cardiovascular events in patients with renal impairment, includ-
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ing those with diabetes.
 
5
 
 Therefore, the results reported here rep-
resent a mean follow-up time of 3.4 years (range, 2.3 to 4.6).
 
Patients
 
The study involved male and female patients, ranging in age from
31 to 70 years, who had received diagnoses of type 2 diabetes and
nephropathy. Nephropathy was defined by the presence on two oc-
casions of a ratio of urinary albumin (measured in milligrams per
liter) to urinary creatinine (measured in grams per liter) from a first
morning specimen of at least 300 (or a rate of urinary protein ex-
cretion of at least 0.5 g per day) and serum creatinine values be-
tween 1.3 and 3.0 mg per deciliter (115 and 265 µmol per liter),
with a lower limit of 1.5 mg per deciliter (133 µmol per liter) for
male patients weighing more than 60 kg. Patients were excluded
if they had received a diagnosis of type 1 diabetes or nondiabetic
renal disease, including renal-artery stenosis. We also excluded pa-
tients who had had a myocardial infarction or had undergone coro-
nary-artery bypass grafting within the previous month, who had
had a cerebrovascular accident or had undergone percutaneous
transluminal coronary angioplasty within the previous six months,
who had had a transient ischemic attack within the previous year,
or who had any history of heart failure before enrollment.
 
4
 
Treatment
 
During the six-week screening phase, patients with hyperten-
sion continued to receive their standard antihypertensive therapy.
If they had been taking angiotensin-I–converting enzyme inhib-
itors or angiotensin-II–receptor antagonists, however, these med-
ications were discontinued and replaced by alternative open-label
medications (diuretics, calcium-channel antagonists, alpha- or beta-
blockers, centrally acting agents, or some combination of these
types of medication). Patients were stratified according to their
base-line level of proteinuria (a urinary albumin-to-creatinine ratio
<2000 or »2000) and randomly assigned to receive either losar-
tan (50 mg) or placebo once daily, along with conventional anti-
hypertensive therapy. After four weeks, the dose of losartan or pla-
cebo was increased to 100 mg or the placebo equivalent once
daily if the trough blood pressure with the patient sitting was above
the target level of a systolic blood pressure of less than 140 mm Hg
and a diastolic blood pressure of less than 90 mm Hg. After an
additional eight weeks, antihypertensive agents of the types de-
scribed above (but not angiotensin-I–converting enzyme inhibi-
tors or angiotensin-II–receptor antagonists) were added or their
doses increased to achieve the target blood pressure.
Throughout the study, patients received the standard of care
for the treatment of diabetes, including measurements of glyco-
sylated hemoglobin and fasting serum glucose concentrations. Vis-
its were scheduled every three months, or more often if necessary,
to monitor the blood pressure and laboratory measurements and
to assess whether adverse events had occurred or end points had
been reached. Patients who discontinued the study drugs early had
follow-up visits every three months until the end of the study; at
these visits, the primary and secondary end points reached were
recorded, the blood pressure was measured, and laboratory meas-
urements were performed. Those who could not return for clinic
visits or a family member was contacted by telephone to determine
whether they had reached the end points of the initiation of dialy-
sis, renal transplantation, or death.
 
Outcome Measures
 
The primary efficacy measure was the time to the first event of
the composite end point of a doubling of the serum creatinine
concentration, end-stage renal disease, or death. The doubling of
the serum creatinine concentration was defined as the first serum
creatinine value that was twice the base-line value, as confirmed by
a second serum creatinine value obtained at least four weeks after
the initial doubling. End-stage renal disease was defined by the need
for long-term dialysis or renal transplantation. The prespecified sec-
ondary end point, morbidity and mortality from cardiovascular
causes, was a composite of myocardial infarction, stroke, first hos-
pitalization for heart failure or unstable angina, coronary or periph-
eral revascularization, or death from cardiovascular causes. Analyses
of the components of both the primary and secondary composite
end points were also prespecified. Other secondary end points in-
cluded the progression of renal disease
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 and changes in the level
of proteinuria.
 
Statistical Analysis
 
Analyses of the primary and secondary end points were per-
formed according to the intention-to-treat principle; we included
data from all randomized patients (with the exception of three pa-
tients who were lost to follow-up), from the time of randomization
through the date of study termination. In a second, per-protocol
analysis, we excluded patients who violated the criteria for inclu-
sion and exclusion and censored patients’ data 14 days after they
permanently discontinued the study medication. A Cox regression
model
 
7
 
 that included the base-line level of proteinuria as a strat-
ification factor and the geographic region as a covariate was used to
determine the hazard ratio for the primary end point and its 95 per-
cent confidence interval. The risk reduction was calculated as 100
percent¬(1¡hazard ratio). In analyses of nonfatal end points,
data for the patients who had died were considered to have been
censored. Event curves are based on Kaplan–Meier analysis.
 
8
 
 We
examined the effect of differences between the groups in the con-
trol of blood pressure by adding the mean arterial pressure during
treatment as a time-dependent covariate in the Cox model and
comparing the effect of losartan estimated by this model with that
estimated by the primary analysis.
The analyses of the progression of renal disease and changes in
the level of proteinuria were based on an on-treatment approach.
For the analysis of the progression of renal disease, we compared
the slopes of the reciprocal of the serum creatinine concentration
 
6
 
of the two treatment groups using a linear random-effects model.
Changes in the level of proteinuria in the two groups were com-
pared by means of a mixed-effects model
 
9
 
 whose terms included
the treatment at each point and the base-line level of proteinuria.
Because one interim analysis used a stopping boundary that was
based on an alpha spending function of the O’Brien–Fleming
type,
 
10
 
 a critical P value of 0.048 was required for the primary
hypothesis. For other outcomes, a P value of less than 0.05 was con-
sidered to indicate statistical significance. All statistical tests were
two-sided.
 
RESULTS
 
A total of 1513 patients were randomly assigned
to receive losartan or placebo once daily, along with
conventional antihypertensive therapy as needed but
excluding angiotensin-I–converting enzyme inhibi-
tors and angiotensin-II–receptor antagonists. The dai-
ly dose of losartan ranged from 50 to 100 mg, with
71 percent of the patients receiving 100 mg. The
base-line characteristics were similar in the two groups
(Table 1). More patients discontinued the study treat-
ment in the placebo group (53.5 percent) than in
the losartan group (46.5 percent). Adverse clinical
events resulted in discontinuation in 17.2 percent of
the patients in the losartan group, as compared with
21.7 percent of those in the placebo group. Increased
serum concentrations of creatinine or potassium led
to the discontinuation of the study medication in 1.5
percent and 1.1 percent, respectively, of the patients
in the losartan group, as compared with 1.2 percent
and 0.5 percent of the patients in the placebo group.
A total of 7.5 percent of the patients in the losartan
The New England Journal of Medicine 
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group and 7.8 percent of those in the placebo group
withdrew their consent. We were able to determine
the status of all patients (except for three patients in
the losartan group who could not be contacted) with
respect to dialysis, transplantation, and death.
 
Blood Pressure
 
At base line, 93.5 percent of the patients (92.3 per-
cent in the losartan group and 94.6 percent in the
placebo group) were receiving antihypertensive ther-
apy. An additional 3 percent of the patients had hy-
pertension but were not receiving antihypertensive
therapy. The trough blood pressure declined progres-
sively during the course of the study. The trough
blood pressure at base line averaged 152/82 mm Hg
in the losartan group and 153/82 mm Hg in the pla-
cebo group; the mean arterial pressure was 105.5
mm Hg in the losartan group and 106.0 mm Hg in
the placebo group (P=0.38); and the pulse pressure
was 69.4 mm Hg in the losartan group and 70.8
mm Hg in the placebo group (P=0.13). At one year,
the values averaged 146/78 mm Hg in the losartan
group and 150/80 mm Hg in the placebo group
(mean arterial pressure, 100.9 mm Hg and 103.1
mm Hg, respectively [P<0.001]; pulse pressure, 67.8
mm Hg and 69.8 mm Hg, respectively [P=0.05]);
at two years, the values were 143/77 mm Hg and
144/77 mm Hg, respectively (mean arterial pressure,
99.1 mm Hg and 99.7 mm Hg, respectively [P=
0.38]; pulse pressure, 66.2 mm Hg and 67.1 mm Hg,
respectively [P=0.37]); and at the end of the study
they were 140/74 mm Hg and 142/74 mm Hg, re-
spectively (mean arterial pressure, 95.9 mm Hg and
96.8 mm Hg, respectively [P=0.59]; pulse pressure,
66.7 mm Hg and 67.4 mm Hg, respectively [P=
0.77]). The various classes of conventional antihy-
pertensive drugs that were used before and during
the study are listed in Table 2.
 
Primary Outcomes
 
According to the intention-to-treat analysis, the
primary composite end point of a doubling of the
serum creatinine concentration, end-stage renal dis-
ease, or death was reached in 327 patients in the losar-
tan group (43.5 percent), as compared with 359 in
the placebo group (47.1 percent) (Fig. 1A). Treatment
with losartan resulted in a 16 percent reduction in
the risk of the primary composite end point (P=
0.02) (Table 3). The decrease in risk remained es-
sentially unchanged (15 percent) after adjustment
for blood pressure (P=0.03). Furthermore, accord-
ing to the per-protocol analysis, among the patients
who continued to receive their assigned study treat-
ment, losartan conferred a 22 percent reduction in the
risk of the primary composite end point (P=0.008).
The intention-to-treat analyses of the individual
components of the primary composite end point are
also shown in Table 3. The risk of a doubling of the
serum creatinine concentration was 25 percent low-
er in the losartan group than in the placebo group
(P=0.006) (Fig. 1B). Losartan also reduced the risk
of end-stage renal disease by 28 percent (P=0.002)
(Fig. 1C). Approximately 20 percent of the patients
died, but there was no significant difference in mor-
tality between the two groups (P=0.88). The risk of
the combined end point of end-stage renal disease
or death was 20 percent lower in the losartan group
 
*Plus–minus values are means ±SD. The differences between the treat-
ment groups were not statistically significant.
†Body-mass index is the weight in kilograms divided by the square of
the height in meters.
‡The mean arterial pressure was calculated as diastolic arterial pres-
sure+(systolic arterial pressure¡diastolic arterial pressure)÷3.
§The pulse pressure was calculated as systolic arterial pressure¡diastolic
arterial pressure.
 
11
 
¶To convert values to micromoles per liter, multiply by 88.4.
¿To convert values to millimoles per liter, multiply by 0.02586.
**To convert values to millimoles per liter, multiply by 0.01129.
††To convert values to millimoles per liter, multiply by 0.6206.
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(N=751)
P
 
LACEBO
 
 
G
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(N=762)
 
Age — yr 60±7 60±7
Sex — no. (%)
Male
Female
462 (61.5)
289 (38.5)
494 (64.8)
268 (35.2)
Race or ethnic group — no. (%)
Asian
Black
White
Hispanic
Other
117 (15.6)
125 (16.6)
358 (47.7)
140 (18.6)
11 (1.5)
135 (17.7)
105 (13.8)
378 (49.6)
136 (17.8)
8 (1.0)
Body-mass index† 30±6 29±6
Blood pressure — mm Hg
Systolic
Diastolic
Mean arterial‡
Pulse§
152±19
82±10
105.5±10.9
69.4±17.4
153±20
82±11
106.0±11.6
70.8±18.1
Medical history — no. (%)
Use of antihypertensive drugs
Angina pectoris
Myocardial infarction
Coronary revascularization procedure
Stroke
Lipid disorder
Amputation
Neuropathy
Retinopathy
Current smoking
693 (92.3)
65 (8.7)
75 (10.0)
1 (0.1)
0
234 (31.2)
65 (8.7)
375 (49.9)
494 (65.8)
147 (19.6)
721 (94.6)
75 (9.8)
94 (12.3)
1 (0.1)
1 (0.1)
271 (35.6)
69 (9.1)
379 (49.7)
470 (61.7)
130 (17.1)
Laboratory variables
Median urinary albumin:creatinine ratio
Serum creatinine — mg/dl¶
Serum cholesterol — mg/dl¿
Total
Low-density lipoprotein
High-density lipoprotein
Serum triglycerides — mg/dl**
Hemoglobin — g/dl††
Glycosylated hemoglobin — %
1237
1.9±0.5
227±56
142±47
45±16
213±180
12.5±1.9
8.5±1.7
1261
1.9±0.5
229±55
142±45
45±15
225±200
12.5±1.8
8.4±1.6
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than in the placebo group (P=0.01) (Fig. 1D and
Table 3). The reductions in the risk of end-stage renal
disease and of end-stage renal disease or death changed
little after correction for blood pressure (26 percent,
P=0.007, and 19 percent, P=0.02, respectively).
 
Secondary Outcomes
 
There was no significant difference between the
losartan group and the placebo group in the com-
posite end point of morbidity and mortality from car-
diovascular causes. Approximately one third of the
patients had a fatal or nonfatal cardiovascular event
(247 in the losartan group [32.9 percent] and 268
in the placebo group [35.2 percent]; risk reduction,
10 percent; P=0.26). There were no significant dif-
ferences in the rates of most of the cardiovascular
end points; the exception was the first hospitalization
with heart failure (89 patients in the losartan group
[11.9 percent], as compared with 127 in the placebo
group [16.7 percent]), for which the risk was reduced
by 32 percent (P=0.005) (Fig. 2). There was a dif-
ference between the number of myocardial infarc-
tions in the losartan group (50 patients [6.7 percent])
and the number in the placebo group (68 patients
[8.9 percent]; risk reduction, 28 percent), but this
difference was not statistically significant (P=0.08).
Losartan also led to an average reduction in the
level of proteinuria (the urinary albumin-to-creatinine
ratio) of 35 percent, whereas in the patients in the
placebo group, the urinary albumin-to-creatinine ratio
tended to increase (P<0.001 for the overall treatment
effect) (Fig. 3). Losartan reduced the rate of decline
in renal function, as assessed by the reciprocal of the
serum creatinine concentration, by 18 percent (me-
dian slope, ¡0.056 dl per milligram per year in the
losartan group, as compared with ¡0.069 dl per
milligram per year in the placebo group; P=0.01).
Likewise, losartan was associated with a 15.2 percent
reduction in the estimated decline in the glomerular
filtration rate (median rate of decline, 4.4 ml per min-
ute per 1.73 m
 
2
 
 of body-surface area per year in the
losartan group, as compared with 5.2 ml per minute
per 1.73 m
 
2
 
 per year in the placebo group; P=
0.01).
 
12,13
 
 These reductions in the rate of decline are
far smaller than those reported for captopril as com-
pared with placebo in patients with type 1 diabetes
nearly a decade ago.
 
1
 
DISCUSSION
 
Our study establishes that losartan, along with
conventional antihypertensive treatment as needed,
confers strong renal protection in patients with type
2 diabetes and nephropathy. The risk of the primary
end point, a composite of a doubling of the serum
creatinine concentration, end-stage renal disease, or
death from any cause, was reduced by 16 percent with
losartan. The primary benefit appeared to be the ef-
fect on the renal components of this composite end
point. In particular, the risk of end-stage renal dis-
ease was reduced by 28 percent with losartan during
an average follow-up of 3.4 years. Extrapolating from
the observed data, we estimate that this reduction
corresponds to an average delay of two years in the
need for dialysis or transplantation. The risk of a dou-
bling of the serum creatinine concentration was also
reduced by 25 percent with losartan. The difference
between the slopes of the reciprocals of the serum
creatinine values and the lower level of proteinuria
provide further evidence of global renal protection
with losartan.
There was a small, time-averaged difference in the
trough blood pressure between the losartan group
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N
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PLACEBO
 
 
 
GROUP
 
 
(
 
N
 
=762)
 
LOSARTAN
 
 
 
GROUP
 
 
(
 
N
 
=751)
 
PLACEBO
 
 
 
GROUP
 
 
(
 
N
 
=762)
 
number (percent)
 
Calcium-channel antagonist
Dihydropyridine
532 (70.8)
406 (54.1)
546 (71.6)
411 (53.9)
585 (77.9)
456 (60.7)
618 (81.1)
487 (63.9)
Diuretic 442 (58.9) 436 (57.2) 629 (83.8) 640 (84.0)
Alpha-blocker 180 (24.0) 184 (24.1) 302 (40.2) 348 (45.7)
Beta-blocker 137 (18.2) 140 (18.4) 256 (34.1) 280 (36.7)
Centrally acting agent 80 (10.7) 84 (11.0) 135 (18.0) 165 (21.7)
Angiotensin-I–converting enzyme inhib-
itor or angiotensin II antagonist
400 (53.3) 376 (49.3) Excluded, per protocol
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and the placebo group. We cannot exclude the pos-
sibility that this small difference had a beneficial effect
on the renal outcomes. However, statistical analysis
that corrected for these small differences confirmed
that the renal protection conferred by losartan ex-
ceeded that attributable to any small differences in
blood pressure. This study extends our knowledge of
the efficacy of antihypertensive therapy in patients
with type 2 diabetes and nephropathy. Previous stud-
ies involving angiotensin-I–converting enzyme in-
hibitors have demonstrated beneficial effects on pro-
teinuria but have not demonstrated the superiority of
blockade of the renin–angiotensin system in slowing
the progression to end-stage renal disease over non-
blockade forms of therapy.
 
14-20
 
 Indeed, studies of the
effects of angiotensin-I–converting enzyme inhibitors
 
Figure 1.
 
 Kaplan–Meier Curves of the Percentage of Patients with the Primary Composite End Point (Panel A) and Its Individual
Components, a Doubling of the Serum Creatinine Concentration (Panel B), End-Stage Renal Disease (Panel C), and the Combined
End Point of End-Stage Renal Disease or Death (Panel D).
The mean follow-up time was 3.4 years (42 months).
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Figure 2. Kaplan–Meier Curves of the Percentage of Patients with a First Hospitalization for Heart Fail-
ure in the Losartan and Placebo Groups.
Subsequent hospitalizations for heart failure were not assessed. There were 88 patients (44 in each
group) who had preexisting heart failure at the time of randomization. When these patients were ex-
cluded from the analysis of this component, there remained a significant difference in the rate of first
hospitalization for heart failure between the two treatment groups. The mean follow-up time was 3.4
years (42 months).
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*In end-point trials, there is often a difference between the risk reduction as determined on the basis of the Cox re-
gression model and the risk reduction as determined on the basis of the crude rates of events. The difference results in
part from the fact that the Cox regression model accounts for the time at risk — i.e., the longer average follow-up in the
losartan group than in the placebo group. To address this aspect of the difference, we present the numbers of events per
100 patient-years of follow-up. In addition, the Cox model accounts for the base-line level of proteinuria (which was a
stratification factor) and the geographic region, as prespecified in the data analysis plan. CI denotes confidence interval.
†The primary end point was a composite of a doubling of the serum creatinine concentration, end-stage renal disease,
or death.
TABLE 3. INCIDENCE OF THE PRIMARY COMPOSITE END POINT AND ITS COMPONENTS.*
END POINT
LOSARTAN GROUP
(N=751)
PLACEBO GROUP
(N=762) P VALUE
RISK
REDUCTION
no. (%)
no./100
patient-yr no. (%)
no./100
patient-yr % (95% CI)
Primary composite end point† 327 (43.5) 15.9 359 (47.1) 18.1 0.02 16 (2 to 28)
Doubling of serum creatinine 
concentration
162 (21.6) 7.9 198 (26.0) 10.0 0.006 25 (8 to 39)
End-stage renal disease 147 (19.6) 6.8 194 (25.5) 9.1 0.002 28 (11 to 42)
Death 158 (21.0) 6.8 155 (20.3) 6.6 0.88 ¡2 (¡27 to 19)
End-stage renal disease or death 255 (34.0) 11.7 300 (39.4) 14.1 0.01 20 (5 to 32)
Doubling of serum creatinine 
concentration and end-stage 
renal disease
226 (30.1) 11.0 263 (34.5) 13.2 0.01 21 (5 to 34)
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on the progression of renal disease and end-stage renal
failure have yielded conflicting results.14,15,20-24 There-
fore, in the absence of a direct comparison between
angiotensin-I–converting enzyme inhibitors and an-
giotensin II antagonists, any extrapolation from the
results obtained with different classes of drugs is spec-
ulative at best.
The benefits of losartan were observed among our
patients, many of whom were already receiving other
therapies, such as aspirin, beta-blockers, and lipid-
lowering agents, as part of sound medical practice.
Similarly, simultaneous therapy with calcium-channel
antagonists did not detract from the beneficial effects
of losartan, despite the recent controversy regarding
the role of calcium-channel antagonists in the pro-
tection of the kidneys and the heart.25-27 In this regard,
it should be noted that in related studies in patients
with type 1 and type 2 diabetes,1,28,29 the benefits of
captopril or irbesartan were not tested in the presence
of concurrent calcium-channel–antagonist therapy.
Furthermore, calcium-channel antagonists have been
shown to augment the production of angiotensin II,30
a response that may be counteracted by concomitant
angiotensin-II–receptor blockade.
There was no significant difference between the
losartan group and the placebo group in the com-
posite secondary end point of morbidity and mortal-
ity from cardiovascular causes. This similarity of in-
cidence may have resulted in part from the relatively
small sample and the strict criteria for enrollment that
excluded patients at high risk for cardiovascular events
including heart failure. We did find a significant dif-
ference in favor of losartan with regard to the rate of
a first hospitalization for heart failure, a component
of this secondary composite end point. This finding in
patients without clinical heart failure at base line ac-
cords well with findings from the Studies of Left Ven-
tricular Dysfunction Prevention study.31 That study,
however, did not include patients with impaired re-
nal function. The Heart Outcomes Prevention Evalu-
ation (HOPE) Study32 and its substudy of patients
with diabetes, MICRO-HOPE,20 showed benefits of
angiotensin-I–converting enzyme inhibition in terms
of the signs and symptoms of heart failure but failed
to show significant differences in hospitalizations for
heart failure. Furthermore, the evaluation of a sub-
group of the HOPE population with renal insuf-
ficiency5 did not show a significant effect on this
outcome. Our findings suggest that angiotensin II
blockade in patients with renal disease decreases the
risk of overt heart failure resulting in hospitalization.
In this population, losartan (plus conventional an-
tihypertensive therapy) demonstrated excellent tol-
erability, similar to that of placebo (plus conventional
antihypertensive therapy), as evidenced by the simi-
lar numbers of patients in the two groups in whom
Figure 3. Median Changes from Base Line in the Level of Proteinuria.
Proteinuria was measured as the urinary albumin-to-creatinine ratio in a first morning specimen. The
mean follow-up time was 3.4 years.
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the study treatment was discontinued because of ad-
verse events. The addition of losartan to a convention-
al antihypertensive treatment regimen did not increase
the incidence of adverse events.
End-stage renal disease continues to be a world-
wide public health concern. Recent estimates by the
National Institutes of Health indicate that diabetes
represents the single largest cause of end-stage renal
disease, accounting for approximately 40 percent of
all cases in the United States between 1994 and
1998.33 Furthermore, the incidence of end-stage re-
nal disease in patients with type 2 diabetes is rising
sharply in many regions of the world and is expected
to double by 2010. The annual costs associated with
end-stage renal disease in the United States reached
$12 billion in 1998 and are expected to surpass
$28 billion by 2010.34 Preventing or delaying the pro-
gression of diabetic nephropathy is therefore an es-
sential management goal. We believe our findings go
a long way toward achieving this goal and may also
have an important economic effect.
In summary, losartan led to significant improvement
in renal outcomes that was beyond that attributable to
blood-pressure control in patients with type 2 dia-
betes and nephropathy.
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